Pick Your Threshold: A Comparison Among Different Methods of Anaerobic Threshold Evaluation in Heart Failure Prognostic Assessment.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
11 2022
Historique:
received: 18 02 2022
revised: 15 04 2022
accepted: 04 05 2022
pubmed: 27 6 2022
medline: 10 11 2022
entrez: 26 6 2022
Statut: ppublish

Résumé

In clinical practice, anaerobic threshold (AT) is used to guide training and rehabilitation programs, to define risk of major thoracic or abdominal surgery, and to assess prognosis in heart failure (HF). AT of oxygen uptake (V.O What is the prognostic power of these different ways to report AT? In this observational cohort study, we screened data of 7,746 patients with HF with a history of reduced ejection fraction (< 40%) recruited between 1998 and 2020 and enrolled in the Metabolic Exercise Combined With Cardiac and Kidney Indexes register. All patients underwent a maximum cardiopulmonary exercise test, executed using a ramp protocol on an electronically braked cycle ergometer. This study considered 6,157 patients with HF with identified AT. Follow-up was median, 4.2 years (25th-75th percentiles, 1.9-5.0 years). Both V.O In HF, V.O

Sections du résumé

BACKGROUND
In clinical practice, anaerobic threshold (AT) is used to guide training and rehabilitation programs, to define risk of major thoracic or abdominal surgery, and to assess prognosis in heart failure (HF). AT of oxygen uptake (V.O
RESEARCH QUESTION
What is the prognostic power of these different ways to report AT?
STUDY DESIGN AND METHODS
In this observational cohort study, we screened data of 7,746 patients with HF with a history of reduced ejection fraction (< 40%) recruited between 1998 and 2020 and enrolled in the Metabolic Exercise Combined With Cardiac and Kidney Indexes register. All patients underwent a maximum cardiopulmonary exercise test, executed using a ramp protocol on an electronically braked cycle ergometer.
RESULTS
This study considered 6,157 patients with HF with identified AT. Follow-up was median, 4.2 years (25th-75th percentiles, 1.9-5.0 years). Both V.O
INTERPRETATION
In HF, V.O

Identifiants

pubmed: 35753386
pii: S0012-3692(22)01184-9
doi: 10.1016/j.chest.2022.05.039
pii:
doi:

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1106-1115

Investigateurs

Stefania Farina (S)
Beatrice Pezzuto (B)
Anna Apostolo (A)
Pietro Palermo (P)
Mauro Contini (M)
Paola Gugliandolo (P)
Irene Mattavelli (I)
Michele Della Rocca (M)
Giovanna Gallo (G)
Federica Moscucci (F)
Anita Iorio (A)
Geza Halasz (G)
Bruno Capelli (B)
Simone Binno (S)
Giuseppe Pacileo (G)
Fabio Valente (F)
Rossella Vastarella (R)
Denise Zaffalon (D)
Cosimo Carriere (C)
Marco Masè (M)
Marco Cittar (M)
Andrea Di Lenarda (A)
Sergio Caravita (S)
Elena Viganò (E)
Giovanni Marchese (G)
Roberto Ricci (R)
Luca Arcari (L)
Domenico Scrutinio (D)
Elisa Battaia (E)
Michele Moretti (M)
Maria Vittoria Matassini (MV)
Matilda Shkoza (M)
Roland Herberg (R)
Antonio Cittadini (A)
Andrea Salzano (A)
Alberto Marra (A)
Eluisa Lafranca (E)
Giuseppe Vitale (G)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Elisabetta Salvioni (E)

Heart failure unit, Centro Cardiologico Monzino, IRCCs, Milan, Italy.

Massimo Mapelli (M)

Heart failure unit, Centro Cardiologico Monzino, IRCCs, Milan, Italy; Cardiovascular Section, Department of Clinical Sciences and Community Health, Milan, Italy.

Alice Bonomi (A)

Heart failure unit, Centro Cardiologico Monzino, IRCCs, Milan, Italy.

Damiano Magrì (D)

Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" Università degli Studi di Roma, Rome, Italy.

Massimo Piepoli (M)

UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy.

Maria Frigerio (M)

Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda-A.O. Niguarda, Milan, Italy.

Stefania Paolillo (S)

IRCCS SDN, Istituto di Ricerca, Naples, Italy.

Ugo Corrà (U)

Cardiology Department, Istituti Clinici Scientifici Maugeri, IRCCS, Veruno Institute, Veruno, Italy.

Rosa Raimondo (R)

Divisione di Cardiologia Riabilitativa, Istituti Clinici Scientifici Maugeri, Tradate, Varese, Italy.

Rocco Lagioia (R)

UOC Cardiologia di Riabilitativa, Mater Dei Hospital, Bari, Italy.

Roberto Badagliacca (R)

Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, "Sapienza," Rome University, Rome, Italy.

Pasquale Perrone Filardi (PP)

Department of Advanced Biomedical Sciences, Federico II University of Naples and Mediterranea CardioCentro, Naples, Italy.

Michele Senni (M)

Heart Failure and Heart Transplant Unit, Department of Cardiology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.

Michele Correale (M)

Department of Cardiology, University of Foggia, Foggia, Italy.

Mariantonietta Cicoira (M)

Poliambulatorio San Gaetano, Thiene, Italy.

Enrico Perna (E)

Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda-A.O. Niguarda, Milan, Italy.

Marco Metra (M)

Division of Cardiology, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Marco Guazzi (M)

Ospedale San Paolo, Università degli studi di Milano, Milan, Italy.

Giuseppe Limongelli (G)

Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Naples, Italy.

Gianfranco Sinagra (G)

Cardiovascular Department, "Azienda Sanitaria Universitaria Giuliano-Isontina," Trieste, Italy.

Gianfranco Parati (G)

Department of Cardiology, Istituto Auxologico Italiano IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

Gaia Cattadori (G)

Unità Operativa Cardiologia Riabilitativa, IRCCS Multimedica, Milan, Italy.

Francesco Bandera (F)

Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; Cardiology University Department, IRCCS Policlinico San Donato, Milan, Italy.

Maurizio Bussotti (M)

Cardiac Rehabilitation Unit, Istituti Clinici Scientifici Maugeri, Scientific Institute of Milan, Milan, Italy.

Federica Re (F)

Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Rome, Italy.

Carlo Vignati (C)

Heart failure unit, Centro Cardiologico Monzino, IRCCs, Milan, Italy.

Carlo Lombardi (C)

Division of Cardiology, Department of Medical and Surgical Specialities, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Angela B Scardovi (AB)

Cardiology Division, Santo Spirito Hospital, Rome, Italy.

Susanna Sciomer (S)

Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, "Sapienza," Rome University, Rome, Italy.

Andrea Passantino (A)

Division of Cardiology, Istituti Clinici Scientifici Maugeri, Institute of Bari, Bari, Italy.

Michele Emdin (M)

Institute of Life Science, Scuola Superiore Sant'Anna, Pisa, Italy; Fondazione Gabriele Monasterio, CNR-Regione Toscana, Pisa, Italy.

Claudio Passino (C)

Institute of Life Science, Scuola Superiore Sant'Anna, Pisa, Italy.

Caterina Santolamazza (C)

Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda-A.O. Niguarda, Milan, Italy.

Davide Girola (D)

Clinica Hildebrand Centro di Riabilitazione, Brissago, Switzerland.

Denise Zaffalon (D)

Cardiovascular Department, "Azienda Sanitaria Universitaria Giuliano-Isontina," Trieste, Italy.

Fabiana De Martino (F)

Heart failure unit, Centro Cardiologico Monzino, IRCCs, Milan, Italy.

Piergiuseppe Agostoni (P)

Heart failure unit, Centro Cardiologico Monzino, IRCCs, Milan, Italy; Cardiovascular Section, Department of Clinical Sciences and Community Health, Milan, Italy. Electronic address: piergiuseppe.agostoni@ccfm.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH